Compass Therapeutics annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Compass Therapeutics R&D Spending Growth & History (CMPX)
Compass Therapeutics's r&d spending was $56.0M for fiscal 2025.
View full Compass Therapeutics company overviewCompass Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $56.0M | $13.6M | +32.18% |
| 2024 | 2024-12-31 | $42.3M | $4.2M | +11.08% |
| 2023 | 2023-12-31 | $38.1M | $8.1M | +27.08% |
| 2022 | 2022-12-31 | $30.0M | $9.7M | +47.50% |
| 2021 | 2021-12-31 | $20.3M | $5.4M | +36.45% |
| 2020 · Dec 31 | 2020-12-31 | $14.9M | −$7.5M | −33.61% |
| 2019 · Dec 31 | 2019-12-31 | $22.4M | — | — |
Compass Therapeutics quarterly r&d spending
Q1.20
Q2.20
Q4.20
Q1.21
Q2.21
Q4.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $19.6M | $3.2M | +19.26% |
| Q1 2026 | 2026-03-31 | $13.4M | $336,000 | +2.57% |
| Q4 2025 | 2025-12-31 | $13.7M | $640,000 | +4.91% |
| Q3 2025 | 2025-09-30 | $12.8M | $4.2M | +48.93% |
| Q2 2025 | 2025-06-30 | $16.4M | $5.2M | +46.90% |
| Q1 2025 | 2025-03-31 | $13.1M | $3.5M | +37.09% |
| Q4 2024 | 2024-12-31 | $13.0M | $606,000 | +4.88% |
| Q3 2024 | 2024-09-30 | $8.6M | −$219,000 | −2.48% |
| Q2 2024 | 2024-06-30 | $11.2M | $951,000 | +9.30% |
| Q1 2024 | 2024-03-31 | $9.5M | $2.9M | +43.45% |
| Q4 2023 | 2023-12-31 | $12.4M | $2.5M | +25.17% |
| Q3 2023 | 2023-09-30 | $8.8M | −$960,000 | −9.80% |
| Q2 2023 | 2023-06-30 | $10.2M | $4.4M | +74.39% |
| Q1 2023 | 2023-03-31 | $6.6M | $2.2M | +50.35% |
| Q4 2022 | 2022-12-31 | $9.9M | — | — |
| Q3 2022 | 2022-09-30 | $9.8M | $6.6M | +210.43% |
| Q2 2022 | 2022-06-30 | $5.9M | $3.0M | +101.79% |
| Q1 2022 | 2022-03-31 | $4.4M | −$289,000 | −6.14% |
| Q3 2021 | 2021-09-30 | $3.2M | −$516,000 | −14.06% |
| Q2 2021 · Jun 30 | 2021-06-30 | $2.9M | −$80,000 | −2.68% |
| Q1 2021 · Mar 31 | 2021-03-31 | $4.7M | $1.1M | +31.73% |
| Q4 2020 | 2020-12-31 | $4.7M | — | — |
| Q2 2021 · Sep 30 | 2020-09-30 | $3.7M | −$2.3M | −38.62% |
| Q1 2021 · Jun 30 | 2020-06-30 | $3.0M | −$2.4M | −44.61% |
| Q4 2020 | 2020-03-31 | $3.6M | — | — |
| Q2 2020 | 2019-09-30 | $6.0M | — | — |
| Q1 2020 | 2019-06-30 | $5.4M | — | — |
Compass Therapeutics r&d spending trends
Over the last five fiscal years, Compass Therapeutics's r&d spending increased from $14.9M to $56.0M, a change of $41.1M. The latest reported quarter, Q2 2026, shows $19.6M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Compass Therapeutics source filings ↗